OLIGONUCLEOTIDE MODULATION OF SPLICING
The present invention relates to the selective modulation of pre-mRNA splicing, in particular, for that involving alternative splicing in disease-related proteins such as those involved in Duschenne's Muscular Dystropy and Spinal Muscular Atrophy.
1 . A method for modulating splicing of a pre-mRNA comprising contacting a cell that produces a pre-mRNA with alternative splicing with a double-stranded RNA of 15-30 bases that targets a splice junction or exonic or intronic sequences adjacent thereto, wherein (a) said alternative splicing produces an “exon-included” product and said double-stranded RNA contains one or more centrally located mismatches; or (b) said alternative splicing produces and “exon-excluded” product and said double-stranded RNA is fully complementary to a target site.
2 . The method of claim 1 , said pre-mRNA encodes a protein that is aberrantly spliced in a disease state.
3 . The method of claim 2 , wherein said protein is the Duchenne muscular dystrophy protein, survival motor neuron 2 protein, the APOB protein, the Bcl-x protein or the insulin receptor protein.
4 . The method of claim 2 , wherein said double-stranded RNA is 19 to about 21 bases in length.
5 . The method of claim 1 , wherein said double-stranded RNA comprises one or more chemically-modified bases.
6 . The method of claim 5 , wherein said chemically-modified base is a 2′-O-methyl modified nucleotide, a nucleotide comprising a 5′-phosphorothioate group, and a terminal nucleotide linked to a cholesteryl derivative or dodecanoic acid bisdecylamide group, a 2′-deoxy-2′-fluoro modified nucleotide, a 2′-deoxy-modified nucleotide, a locked nucleotide, an abasic nucleotide, 2′-amino-modified nucleotide, 2′-alkyl-modified nucleotide, morpholino nucleotide, a phosphoramidate, or a non-natural base comprising nucleotide.
7 . The method of claim 5 , wherein the guide strand or the passenger strand contains the chemically-modified base.
8 . The method of claim 5 , wherein the guide and passenger strands both contain at least one chemically-modified base.
9 . The method of claim 1 , wherein said double-stranded RNA comprises at least 15 bases and said first base mismatch is flanked by at least 7 bases on both the 5′ and 3′ ends of said double-stranded RNA.
10 . The method of claim 1 , wherein said first base mismatch is in the guide strand.
11 . The method of claim 1 , wherein said double-stranded RNA further comprises a second base mismatch.
12 . The method of claim 11 , wherein said second base mismatch is in the passenger strand.
13 . The method of claim 11 , wherein said first and second base mismatches are in the guide strand.
14 - 22 . (canceled)
23 . The method of claim 1 , wherein said double-stranded RNA targets a splice junction sequence, or an exonic sequence flanking a splice junction sequence, or an intronic sequence flanking a splice junction sequence.
24 - 25 . (canceled)
26 . The method of claim 1 , wherein splicing of said pre-mRNA is shifted such that an alternative exon is included.
27 . The method of claim 1 , wherein splicing of said pre-mRNA is shifted such than an alternative exon is excluded.
28 . The method of claim 1 , wherein said double-stranded RNA comprises a non-natural internucleotide linkage.
29 . The method of claim 28 , wherein the non-natural internucleotide linkage is a phosphorothioate linkage, and/or is in a guide strand, passenger strand or both.
30 . (canceled)
31 . A method for modulating splicing, in a subject, of an pre-mRNA encoding a disease protein and having alternative splicing comprising administering to said subject a double-stranded RNA of 15-30 bases that targets a splice junction or exonic or intronic sequences adjacent thereto, wherein (a) said alternative splicing produces an “exon-included” product and said double-stranded RNA contains one or more centrally located mismatches; or (b) said alternative splicing produces and “exon-excluded” product and said double-stranded RNA is fully complementary to a target site.
32 - 65 . (canceled)
66 . A composition of matter comprising a double-stranded RNA of 15-30 bases that that targets a splice junction or exonic or intronic sequences adjacent thereto in a pre-mRNA, wherein (a) said alternative splicing produces an “exon-included” product and said double-stranded RNA contains one or more centrally located mismatches; or (b) said alternative splicing produces and “exon-excluded” product and said double-stranded RNA is fully complementary to a target site.
67 - 91 . (canceled)